Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis
about
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature reviewClinical management of infections caused by multidrug-resistant EnterobacteriaceaeBeyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-LactamasesGenetic Characterization of Carbapenem-Resistant Enterobacteriaceae and the Spread of Carbapenem-Resistant Klebsiella pneumonia ST340 at a University Hospital in ThailandEmpiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing EnterobacteriaceaeAn update on the management of urinary tract infections in the era of antimicrobial resistance.Resistant pathogens, fungi, and viruses.Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.Modulation of Membrane Influx and Efflux in Escherichia coli Sequence Type 131 Has an Impact on Bacterial Motility, Biofilm Formation, and Virulence in a Caenorhabditis elegans ModelTrends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coliFecal carriage of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae in Egyptian patients with community-onset gastrointestinal complaints: a hospital -based cross-sectional study.Dominance of CTX-M-type extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China.Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rodsCeftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.War wound treatment complications due to transfer of an IncN plasmid harboring bla(OXA-181) from Morganella morganii to CTX-M-27-producing sequence type 131 Escherichia coli.Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremiaAminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.Intestinal decolonization of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL): a retrospective observational study in patients at risk for infection and a brief review of the literature.Mechanisms of antimicrobial resistance in Gram-negative bacilli.Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremiaCefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy.Genome Sequencing of Four Multidrug-Resistant Enterobacter aerogenes Isolates from Hospitalized Patients in BrazilEfficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.Recommended Initial Antimicrobial Therapy for Emphysematous Pyelonephritis: 51 Cases and 14-Year-Experience of a Tertiary Referral Center.Neonatal infections with multidrug-resistant ESBL-producing E. cloacae and K. pneumoniae in Neonatal Units of two different Hospitals in Antananarivo, Madagascar.A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing EnterobacteriaceaeOutcome of Antimicrobial Therapy of Pediatric Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrosImpact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis.Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections.Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.
P2860
Q26739860-23BE8B08-A657-4DF1-811F-D83E18F08ACFQ26796605-D4BCF7DA-4047-496F-8702-9F89C20DD7F8Q28246841-2E80D5CC-972F-402C-892E-43CDC1F6753DQ28249617-5303B2D7-3E25-4106-AD8D-29C5D39CAA29Q28548463-1ABE8395-A598-4819-8C05-1CFBBAC3B65BQ28551534-38011B60-A5A1-4C19-AC0E-B5EC90BCC677Q30244815-9AE2A3D5-418B-4296-A508-6771849997E5Q30301237-E3E21E4C-26C9-4ECD-97E5-BE002A6648F8Q30354148-107D355A-F9BF-4074-A1B4-47BFA7B455ADQ30385057-AAAB8150-1AE1-409B-909C-D37FB213A9B2Q30914624-3E6C3A0A-526A-4CDE-91FE-50A343D592A3Q33598276-220E9A75-820A-464B-97A4-126125F6B9A9Q33776486-60E3F5BC-7142-44F4-853E-87C257CF704FQ33795954-CE1B75DD-A100-47F5-BE59-97FF97CE8B38Q33830187-AC77B57D-9E87-4351-A875-6E4800E39F28Q35030247-EC413DCC-0FF6-424D-973D-73E0FB3A936BQ35209282-C7521AE6-7C69-4B16-AB61-6B3A230C4B6DQ35545954-85B9C883-15AE-4E6D-97D8-6CC6DAD2A747Q35552650-F253268D-2026-4F26-832A-BDBC355C9301Q35607676-86052792-F84F-4667-AEAA-ABDB00FDDC82Q35715650-9E62168F-2F28-4687-98C0-4F7BC21146B0Q35805673-EF7C23A9-CAE8-4638-A4FE-9882365637F0Q35825390-A00B394A-FDE7-4179-A402-11991AC9AC75Q35935319-89F1D7D1-1B41-4B45-A33D-4FCBDF8F4017Q35960721-8A1E1FB2-B349-43BF-AE7B-F2946B1A03E0Q36107315-44CF7F8D-F7DA-41D7-8AEF-C94C934AF4E5Q36150730-8CC91E14-2C0B-4269-956E-F2041C3C5E9DQ36189415-329C76EA-A583-49A1-BF5B-FE6E48D1A1E9Q36294413-231A8E72-CACF-47D7-A93A-0A354D338F6DQ36438937-9B8CB58B-E1D3-4547-9403-961A3C7AB7C7Q36461121-E7374792-2765-4F7A-9780-920FAD7F1097Q36901488-6BC30AAE-5A57-45C9-B9A0-525F36B0AF3BQ36992856-6B0CA44A-39B5-42C0-8FDC-9F7E13F78EB2Q36994466-562CE6D0-5948-42AC-BBEC-6E0392E9D332Q37023191-61D65A64-D108-4BA9-900D-51C9ADED1FF8Q37518263-E8B36546-7CBE-4592-8B82-74FAD38C1E89Q37612207-65B3C316-D18E-44AC-9A71-AA5A2E05394CQ38120490-63154A73-3C81-4B88-BF12-7B0504359FABQ38145311-E3E279E0-0E51-4D84-9C15-F658B9CF2AE3Q38147851-D2280008-3F8F-49B7-AA4C-983603DF4FF8
P2860
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Carbapenems versus alternative ...... matic review and meta-analysis
@ast
Carbapenems versus alternative ...... matic review and meta-analysis
@en
Carbapenems versus alternative ...... matic review and meta-analysis
@nl
type
label
Carbapenems versus alternative ...... matic review and meta-analysis
@ast
Carbapenems versus alternative ...... matic review and meta-analysis
@en
Carbapenems versus alternative ...... matic review and meta-analysis
@nl
prefLabel
Carbapenems versus alternative ...... matic review and meta-analysis
@ast
Carbapenems versus alternative ...... matic review and meta-analysis
@en
Carbapenems versus alternative ...... matic review and meta-analysis
@nl
P2093
P2860
P31
P3181
P356
P1476
Carbapenems versus alternative ...... matic review and meta-analysis
@en
P2093
G. S. Tansarli
K. Z. Vardakas
M. E. Falagas
P. I. Rafailidis
P2860
P304
P3181
P356
10.1093/JAC/DKS301
P407
P577
2012-12-01T00:00:00Z